Innosuisse application

Back to the list
by AS | 22 July 2021
Image Innosuisse application

Innosuisse accepted SULFISCON's application to support the development of an allosteric modulator of CSE as a treatment of pathologic calcification disorders

Next article >

SULFISCON selected for BIOPOLE STARTUP FUND

On the 5th July 2023, BIOPOLE announced that it has selected SULFISCON for its BIOPOLE STARTUP FUND award, worth 45k CHF in the first year. This will help SULFISCON develop its medicinal chemistry program and support its ongoing research